CDK4 and prostate carcinoma: With the introduction of effective palliative systemic treatments, e.g., CDK4/6-inhibitors in breast cancer, and enzalutamide and abiraterone in prostate cancer, pts with bone metastases originating from these malignancies may have a life expectancy of several years [19,20].